The 5-HT1A receptor in schizophrenia: A promising target for novel atypical neuroleptics?

Journal of Psychopharmacology

Volumn 15, Issue 1, 2001, Pages 37-46

  Bantick, R A ^a   Deakin, J F W ^b   Grasby, Paul ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Atypical antipsychotic; Dopamine; Glutamate; Review; Schizophrenia

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; BUSPIRONE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; PINDOLOL; QUETIAPINE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; TANDOSPIRONE; ZIPRASIDONE; SEROTONIN 1 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR;

CATALEPSY; CLINICAL TRIAL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIMBIC SYSTEM; NEGATIVE SYNDROME; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RECEPTOR DENSITY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; ANIMAL; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SCHIZOPHRENIA; SEROTONIN AGONISTS;

EID: 0034745153     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110101500108     Document Type: Review

References (109)

1. Serotonin-glutamate interactions: A new target for antipsychotic drugs
2. Prevention by (±)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol
3. Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia
4. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex
5. 1A receptor selective ligands (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons
6. 1A receptors
7. 2A receptors in the rat medial prefrontal cortex: And iontophoretic study
8. 1A receptor in primate brain neurones and glial cells
9. 1A receptor mRNA in schizophrenic orbital frontal cortex
10. 1A receptor by clozapine measured using PET scanning
11. A review of central 5-HT receptors and their function
12. 1A receptors are not involved in clozapine's lack of cataleptic potential
13. Facilitation of dopamine release in vivo by serotonin agonists: Studies with microdialysis
14. Serotonin-facilitated dopamine release in vivo: Pharmacological characterisation
15. Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats
16. 1B agonists: Involvement of the hippocampoaccumbens pathway
17. The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms
18. Effects of buspirone in seven schizophrenic patients
19. 2A receptor mRNA in human brain
20. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia
21. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain
22. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia
23. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia
24. 1A receptors control 5-HT release in the rat medial prefrontal cortex
25. Extrapyramidal syndromes: Primate models as predictors of clinical response
26. 1 receptor stimulation
27. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (±)-8-hydroxy-2-(di-n-propylamino) tetralin
28. 1A receptor by clozapine revealed by positron emission tomography in the primate brain
29. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers
30. Cellular localisation of serotonin 1A, 1B and uptake sites in cingulate cortex of the rat
31. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group
32. A two-process theory of schizophrenia: Evidence from studies in post-mortem brain
33. Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia
34. 4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia
35. 1A receptor agonists: Recent developments and controversial issues
36. 1A receptor agonist, alnespirone (S-20499), affecting dopaminergic systems in the rat brain?
37. 1A receptors in human hippocampus
38. The emerging role of clozapine in the treatment of movement disorders
39. Drugs which antagonise 5-hydroxytryptamine
40. 2 dopamine antagonists
41. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex diasylates of freely moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release
42. 1A, and 5-HT1B receptors
43. Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely moving rats
44. An open trial of buspirone added to neuroleptics in schizophrenic patients
45. Enhancement by ipsapirone of dopamine release in the rat striatum
46. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
47. 1A receptor-induced inhibition of 5-HT neuronal activity in the rat
48. 11C]WAY-100635
49. 3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain
50. 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia
51. 1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbans
52. The effect of ipsapirone and S (-)-pindolol on dopamine release in rat striatum and nucleus accumbens
53. 1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens
54. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis
55. 2A, antagonist, potentiates the ability of R (+)-8-OH-DPAT to increase extracellular dopamine (DA-ext) levels in rat medial prefrontal cortex (mPFC)
56. 1A receptors in the living human brain using [carbonyl-11]WAY-100635: PET with anatomic standardisation technique
57. 1A receptors mediate inhibition of tyrosine hydroxylation in rat striatum
58. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenia
59. Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat
60. Serotonin-dopamine interaction and its relevance to schizophrenia
61. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
62. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons
63. Drug treatment of the negative symptoms of schizophrenia
64. Dopamine, the prefrontal cortex and schizophrenia
65. Therapeutic implications of the hyperglutamatergic NMDA antagonists
66. 1A receptors and their modulation of the activity of serotonergic and dopaminergic neurones in rats
67. 1A) receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535
68. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release
69. 1A receptors in human brain tissue
70. The effects of clozapine on cognitive functioning in schizophrenia
71. Receptor reserve for 5-hydroxytryptamine 1A mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists
72. An overview of the mechanism of action of clozapine
73. The role of serotonin in antipsychotic drug action
74. 1A) agonist properties: I. Receptoral and neurochemical profile in comparison with clozapine and haloperidol
75. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol
76. 2 receptors in chronic schizophrenics
77. Preferential activation of cortical dopamine neurotransmission by clozapine: Functional significance
78. Serotonergic involvement in haloperidol-induced catalepsy
79. 1A receptors
80. 35S]GTPγS binding study
81. 2 receptors
82. 1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbans and striatum
83. Advances in psychopharmacology - Schizophrenia
84. Acute exacerbation of psychosis with buspirone
85. Serotonin receptors in the human brain - III. Autoradiographic mapping of serotonin-1 receptors
86. Effects of dopamine antagonists in a two-way active avoidance procedure in rats: Interactions with 8-OH-DPAT, ritanserin, and prazosin
87. 1A ligands in preclinical behavioural models for antipsychotic and extrapyramidal effects
88. 1A agonist ± 8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine
89. 2C receptor antagonist
90. 1A receptor activation
91. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex
92. The role of serotonin in schizophrenia
93. Influence of serotonergic drugs on in vivo dopamine extracellular output in rat striatum
94. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat
95. Ziprasidone (CP-88 059) a new antipsychotic with combined dopamine and serotonin receptor antagonist activity
96. 1A receptors in ventral prefrontal cortex in schizophrenia
97. Use of buspirone in the treatment of schizophrenia
98. 1a receptor activation
99. Serotonin-1A receptors are increased in postmortem prefrontal cortex in schizophrenia
100. Effects of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia
101. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential?
102. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat
103. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy
104. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat
105. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomised trials
106. 1A receptors in the rat prefrontal cortex
107. A biological and pharmacological suggestion about certain mental disorders
108. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes
109. Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat